Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PureTech Health ( (GB:PRTC) ) has shared an update.
PureTech Health has reported the vesting of restricted share units granted in May 2023 to President Eric Elenko under its Performance Share Plan, following the achievement of performance conditions measured over three years to the end of 2025. The vested RSUs were settled on 12 March 2026 through the issuance of 112,509 ordinary shares, net of payroll tax withholdings, at a reference price of 123.67 pence per share.
Following this issuance, PureTech’s total issued ordinary share capital stands at 257,927,489 shares, of which 14,859,738 are held in treasury by the company. The transaction, conducted on the London Stock Exchange, reflects ongoing equity-based compensation for senior management and results in a small increase in the company’s free-float share count while signaling continued alignment of executive incentives with shareholder interests.
The most recent analyst rating on (GB:PRTC) stock is a Hold with a £139.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Spark’s Take on GB:PRTC Stock
According to Spark, TipRanks’ AI Analyst, GB:PRTC is a Neutral.
PureTech Health’s overall score reflects a balance of strong liquidity and promising clinical developments against challenges in profitability and technical weakness. The company’s strategic initiatives and recent positive trial results provide a cautiously optimistic outlook, but operational risks and funding uncertainties remain significant factors.
To see Spark’s full report on GB:PRTC stock, click here.
More about PureTech Health
PureTech Health plc is a hub-and-spoke biotherapeutics company listed on Nasdaq and the London Stock Exchange that focuses on developing therapeutics based on validated pharmacology to address significant unmet patient needs. Its capital-efficient R&D model has produced dozens of therapeutic candidates, including three U.S. FDA-approved treatments, which are advanced via dedicated structures supported by external capital to accelerate patient access and build long-term shareholder value.
Average Trading Volume: 417,817
Technical Sentiment Signal: Strong Sell
Current Market Cap: £297.9M
Learn more about PRTC stock on TipRanks’ Stock Analysis page.